Nektar Therap (NKTR)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and interna...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Nektar Therap Analyst Rating
View moreForecast & Rating
Sep 16, 2026Price forecast
$144.40111.23%
Forecast & RatingStrong buy
12analysts
- Strong buy75.00%
- Buy8.33%
- Hold16.67%
- Sell0.00%
- Strong sell0.00%
News
- TradingView · 1 day ago, 10:05 AM
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
- Global Report · 2 days ago, 11:33 AM
The Identity Crisis Portfolio: Who’s Building the Future and Who’s Faking It
- Global Report · 2 days ago, 10:12 AM
Record Revenues at nLIGHT and QuinStreet Mask Biotech Cash Burn Across Diverse U.S. Equity Group
- Global Report · 2 days ago, 09:18 AM
Business Models in the Real World: Ginkgo's Transition Pains and the Aggregation of Infrastructure
- Global Report · 2 days ago, 07:01 AM
The Infrastructure Pivot: Repurposing Assets for the Next Paradigm
- Simplywall · Sep 6 at 04:22 PM
Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In?
